Skip to main content
Addgene

pcDNA3-AU1-mTOR-R2505P
(Plasmid #26038)

Full plasmid sequence is not available for this item.

Loading...

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 26038 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pcDNA3
  • Backbone manufacturer
    Invitrogen
  • Backbone size w/o insert (bp) 5400
  • Vector type
    Mammalian Expression

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    mammalian target of rapamycin-R2505P
  • Alt name
    mTOR
  • Species
    R. norvegicus (rat)
  • Insert Size (bp)
    7700
  • Mutation
    R2505P
  • Entrez Gene
    Mtor (a.k.a. Frap1, RAFT1)
  • Tag / Fusion Protein
    • AU1 (N terminal on insert)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site Hind III (not destroyed)
  • 3′ cloning site Not I (not destroyed)
  • 5′ sequencing primer T7
  • 3′ sequencing primer Sp6
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pcDNA3-AU1-mTOR-R2505P was a gift from Fuyuhiko Tamanoi (Addgene plasmid # 26038 ; http://n2t.net/addgene:26038 ; RRID:Addgene_26038)
  • For your References section:

    Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F. Oncogene. 2010 May 6. 29(18):2746-52. 10.1038/onc.2010.28 PubMed 20190810